Trial Profile
An Open-label, Randomized, 2-Period, 2-Sequence Crossover Study to Evaluate the Pharmacokinetics, Bioavailability and Safety of Tofacitinib Once-daily Modified-Release (MR) Formulation in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Aug 2015
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 28 Aug 2015 New trial record